Blueprint Medicines Corp - Asset Resilience Ratio
Blueprint Medicines Corp (BPMC) has an Asset Resilience Ratio of 37.97% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Blueprint Medicines Corp (BPMC) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Blueprint Medicines Corp's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Blueprint Medicines Corp balance sheet assets.
Liquid Assets Composition Over Time
This chart breaks down Blueprint Medicines Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Blueprint Medicines Corp strategic investment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $453.99 Million | 37.97% |
| Total Liquid Assets | $453.99 Million | 37.97% |
Asset Resilience Insights
- Very High Liquidity: Blueprint Medicines Corp maintains exceptional liquid asset reserves at 37.97% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Blueprint Medicines Corp Industry Peers by Asset Resilience Ratio
Compare Blueprint Medicines Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Blueprint Medicines Corp (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Blueprint Medicines Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 43.52% | $513.47 Million | $1.18 Billion | -17.41pp |
| 2023-12-31 | 60.93% | $639.36 Million | $1.05 Billion | -0.20pp |
| 2022-12-31 | 61.14% | $825.28 Million | $1.35 Billion | +39.80pp |
| 2021-12-31 | 21.34% | $267.17 Million | $1.25 Billion | +10.44pp |
| 2020-12-31 | 10.89% | $187.21 Million | $1.72 Billion | -41.33pp |
| 2019-12-31 | 52.23% | $369.62 Million | $707.69 Million | -26.63pp |
| 2018-12-31 | 78.86% | $425.95 Million | $540.12 Million | +40.71pp |
| 2017-12-31 | 38.15% | $273.05 Million | $715.74 Million | -19.17pp |
| 2016-12-31 | 57.32% | $162.09 Million | $282.80 Million | +57.25pp |
| 2015-12-31 | 0.07% | $119.00K | $178.90 Million | -0.17pp |
| 2014-12-31 | 0.24% | $119.00K | $49.92 Million | -- |
About Blueprint Medicines Corp
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast … Read more